Diagnostics And Consultancy Center Pulmed EOOD — Clinical Trial Site

9 Registered trials

4 Currently recruiting

Organisation

Diagnostics And Consultancy Center Pulmed EOOD

Location

Plovdiv, Bulgaria

Identifier

ORG-100044734

Address

Ulitsa Perushtitsa 1a, 4002, Bulgaria

Departments

10024
Dermatology and Venereology
Dermatology and venerology
Endocrinology and Metabolic Diseases Consulting Room
Medical office for skin and venereal diseases
N/A
Not applicable

Clinical trials at this site (9)

Search interface

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety … Recruiting

2024-520098-12-00 Cutaneous Lupus Erythematosus 4 2026-02-16
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Prurigo Nodularis 5 2024-12-12
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Chronic Spontaneous Urticaria 5 2024-12-16
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended

2022-503004-24-00 Influenza virus 5 2023-10-20
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Ch… Ended

2024-516988-87-00 Chronic Inducible Urticaria 4 2022-11-09